This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).

The investigators will assess the 18-month safety and potential efficacy of autologous MSCs as therapy for ADPKD. A total of 6 patients with ADPKD IV injection of high doses 2×106 of autologous mesenchymal stem cells / kg their weight, which will be derived from biopsies of their bone marrow. Assessments will be made at 1, 3, 6, 12 and 18 months after cell injection. Changes in GFR rate were evaluated by scan isotope.

Inclusion Criteria:

• Male and Female
• ADPKD symptoms
• ADPKD confirmed with sonography and genetic testing
• Patient's age between 18 - 60 years
• GFR GFR 25-60 mL/min/1.73 m2
• Ability to understand and willingness to sign consent from

Exclusion Criteria:

• Pregnancy or breastfeeding
• Associated Cardiovascular disease
• Diabetes requiring medical intervention
• Other systemic diseases involving the kidneys, such as cancer, autoimmune diseases, blood diseases, liver disease, etc.
• Hospitalization due to illness in the last two months
• Life expectancy of less than two years
• Any allergies to the ingredients used in the cell culture